⌕
Mineralys Therapeutics · MLYS · Nasdaq
Tenet 55 · Mixed
Compare
$14.48−0.34%At closeTenet 55 · Mixed
$14.48−0.05 (−0.34%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Mineralys Therapeutics (MLYS) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+87.0%) and Returns vs FCF (n/m). Both visible in the receipts below.
The four lines that matter · FY22–FY25
Revenue ($M)—
0.0
FY22→FY25CAGR —
Net income ($M)▲13.0%
−154.7
FY22→FY25CAGR —
Free cash flow ($M)▲14.4%
−142.4
no value for 1 of 4 yearsCAGR —
Diluted EPS▲37.4%
−2.29
FY22→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+87.0%

36.2mn → 67.7mn diluted shares since FY23. Rising share count dilutes EPS. Growth must outrun it.

Capex
$15.0K

−84.4% YoY in FY25.

Returns vs FCF
n/m

$0.4M returned vs $−142.4M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.

What the income statement says · FY22–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−132.0R&D−38.6SG&A−170.6Op income16.0Tax & other−154.7Net income

Margin trend · direction beats level
108530%sector median net margin ~3%FY22FY25

This filer reports no gross profit or operating income line, so those margins are not drawn.

The receipt · income statement · FY22–FY25 USD millions except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7603, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22YoYCAGR 22→25
Revenue & profitability
Revenue
—0.00.00.00.0——
Cost of revenue
—0.00.00.00.0——
Gross profit
—0.00.00.00.0——
Research & development
292.8132.0168.670.426.3▼21.7%+71.3%
Selling, general & admin
96.938.623.814.35.2▲62.0%+94.7%
Total operating expenses
389.7170.6192.484.731.5▼11.3%+75.7%
Operating incomefeeds ROC rank
−389.7−170.6−192.4−84.7−31.5▲11.3%—
Other income, net
19.816.014.612.81.7——
Pretax income
−370.0−154.7−177.8−71.9−29.8▲13.0%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−370.0−154.7−177.8−71.9−29.8▲13.0%—
Per share
Diluted EPSbuyback-sensitive
−4.28−2.29−3.66−1.99−5.77▲37.4%—
Diluted shares (mn)
88.9967.6648.5436.195.17▲39.4%+135.7%
Margins
† TTM = trailing four quarters through 2026-09-30.
CSV export is on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-12 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.